0A

Medacta Group SALSE Medacta Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

2.787

Small

Exchange

XLON - London Stock Exchange

0A05.L Stock Analysis

0A

Uncovered

Medacta Group SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

68/100

Moderate score

Market cap $B

2.787

Dividend yield

0.47 %

Shares outstanding

19.96 B

Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino and currently employs 1,537 full-time employees. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.

View Section: Eyestock Rating